MaaT Pharma's Shares Plunge 56% to €2.97 Following Negative CHMP Signal
MaaT Pharma's stock experiences a sharp decline this Thursday midday, with the share price of the Lyon-based biotech falling to €2.97. The drop comes after the company announced a negative trend from the CHMP regarding its European authorization request for Xervyteg.
Negative CHMP Signal on Xervyteg Causes Share Price to Halve
MaaT Pharma was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency of a trend towards a negative opinion on its conditional marketing authorization application for Xervyteg (MaaT013), intended for the treatment of acute graft-versus-host disease. The formal vote by the CHMP is expected in June.
The stock plummeted by 55.93% to €2.97, after hitting a session low of €2.60, a historical low (previous record low of €3.55 reached on November 17, 2025).
The MaaT013/Xervyteg file constitutes a significant portion of the expectations surrounding MaaT Pharma, with the candidate being the most advanced program in the portfolio and subject to a conditional MA application in Europe. The 'negative trend' indicated by the CHMP before its June vote represents a major regulatory setback. In the event of a formal negative opinion, the European registration trajectory would be compromised, although the company indicates it plans to request a re-examination of the file.
Share Price Breaks All Technical Supports and Falls Below €3
Today's downturn shatters the entire graphical structure of the stock. The price at €2.97 significantly falls below the MM20 at €6.38, the MM50 at €6.32, and the MM200 at €5.35. The gap of over 44% above the long average reflects the magnitude of the shock: no intermediate cushioning zones held. The support at €5.30 identified in the technical data was shattered right at the opening, with the stock establishing itself well below.
The one-month volatility was at 20.22 before the session, already a high level for a biotech, now rewritten by today's movement. The RSI at 56 does not yet reflect the intraday collapse, the smoothed calculation over several sessions gradually absorbing the shock. The next milestone identified: the publication of the first quarter 2026 revenue, expected on May 26. The formal CHMP vote in June will be the next significant event for the Xervyteg file.
